154 related articles for article (PubMed ID: 7986719)
1. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
2. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
4. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
6. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
[TBL] [Abstract][Full Text] [Related]
7. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
8. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
12. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
[TBL] [Abstract][Full Text] [Related]
13. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
15. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
Smith KJ
Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group.
Poon MC; Aledort LM; Anderle K; Kunschak M; Morfini M
Transfusion; 1995 Apr; 35(4):319-23. PubMed ID: 7701550
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate.
Morfini M; Longo G; Berntorp E; Cinotti S; Filimberti E; Messori A; Nilsson IM; Rossi Ferrini P
Thromb Res; 1993 Aug; 71(3):175-84. PubMed ID: 8211885
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
Kim HC; Matts L; Eisele J; Czachur M; Saidi P
Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
[No Abstract] [Full Text] [Related]
20. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
